What is AIxCrypto Holdings, Inc. (AIXC)?

AIxCrypto Holdings, Inc. (AIXC) is a stock in the Technology sector, Software - Infrastructure industry. View full analysis on Stocks360.

What is the current price of AIXC?

The current price of AIXC is $1.37. Prices are updated in real time on Stocks360.

What is AIXC's price-to-earnings (PE) ratio?

AIXC's trailing twelve-month PE ratio is -0.15, based on current price and earnings per share data available on Stocks360.

What is AIXC's market capitalization?

AIXC's market capitalization is $27,721,939.00, placing it in the small-cap tier.

AIxCrypto Holdings, Inc. (AIXC)

Stock analysis · NASDAQ · Technology · Software - Infrastructure

$1.37

Market Cap

$27.72M

PE (TTM)

-0.15

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.57

Day Range

$1.09 – $1.53

52-wk Range

$0.59 – $5.97

Avg Volume

N/A

Volume

23.07K

AIxCrypto Holdings, Inc. (AIXC) is a publicly traded company in the Technology sector. Latest price: $1.37. Market cap $27.72M. Trailing PE -0.15. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $2.85 2026-10-26 · $1.07 (-62.46%)

Earnings

Most Recent

Aug 7, 2026

EPS $-0.21 vs est. $-70.00

Beat by $69.79

Next Earnings

Nov 17, 2026

EPS estimate $-70.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About AIxCrypto Holdings, Inc.

AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.15×
P/S (TTM)	0.00×
P/B	4.89×
PEG	0.01×
P/FCF (TTM)	-2.27×
EV / EBITDA	-1.23×
EV / Sales	0.00×
Earnings Yield	-82.40%
Free Cash Flow Yield	-44.02%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$27.18M
Net Income (TTM)	-$22.84M
Free Cash Flow (TTM)	-$12.29M
Net Debt	-$537.77K
Working Capital	$4.62M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-97.40%
Return on Invested Capital	-281.17%